CounterX Therapeutics to Showcase Breakthrough Therapies at CPDD 2026 Meeting

CounterX Therapeutics Leads the Charge Against Opioid Crisis

CounterX Therapeutics, a pioneering biotechnology firm, is set to make an impactful presentation at the 88th Annual College on Problems of Drug Dependence (CPDD) Scientific Meeting from June 13-17, 2026, in Portland, Oregon. With a strong focus on combating the alarming opioid overdose epidemic, the company aims to highlight its innovative antibody therapeutics designed to prevent fentanyl overdoses and support addiction recovery.

In his remarks, Shawn Iadonato, the Chief Executive Officer of CounterX Therapeutics, expressed the company’s enthusiasm about participating in the CPDD event. This conference is regarded as a premier platform for experts in substance use disorders and overdose prevention. Iadonato stated, "We are pleased to share CounterX's progress in advancing next-generation approaches designed to help address the devastating impact of fentanyl overdose."

The conference will feature various sessions, including keynotes and discussions centered on the evolving drug overdose crisis and the role of medical countermeasures. Two significant presentations from CounterX Therapeutics will take place:

1. Title: Antibody-based therapeutics to protect against overdose from opioids and poly-drug exposures
Presenter: Dr. Marco Pravetoni
Date: June 15, 2026
Time: 1 PM - 2 PM Pacific Time
Location: OCC Level 2, Oregon Ballroom 202

2. Title: CTRX-101, an Anti-Fentanyl Monoclonal Antibody for Overdose Prevention in Patients with Opioid Use Disorder
Presenter: Dr. Shawn Iadonato
Date: June 16, 2026
Time: 8 AM - 9 AM Pacific Time
Location: OCC Level 1, Oregon Ballroom 101

A Revolutionary Approach with CTRX-101

The crown jewel of CounterX's offerings, CTRX-101, is a groundbreaking, once-monthly monoclonal antibody aimed at preventing fentanyl overdoses. This innovative treatment is administered via a long-acting subcutaneous injection and does not fall under the classifications of opioids or controlled substances, making it a safer option for patients.

In preclinical trials, CTRX-101 demonstrated commendable results without serious adverse effects, even when combined with other therapies for opioid use disorder (OUD). Furthermore, it has shown no indication of inducing opioid withdrawal symptoms, representing a significant advancement in maintaining patient safety while striving for recovery.

The Fight Against the Opioid Epidemic

CounterX Therapeutics stands at the forefront of the battle against the opioid crisis, utilizing cutting-edge biotechnology to develop life-saving therapies. The company's commitment extends not only to innovation but also to fostering social impact in communities ravaged by addiction.

Dr. Marco Pravetoni, the founder and Chief Scientific Officer, remarks that the development of these therapies is a crucial step in addressing the profound challenges associated with opioid use and overdose. The mission of CounterX is clear: to provide effective solutions that can save lives and help individuals reclaim their futures.

As the CPDD conference nears, the excitement surrounding CounterX Therapeutics continues to build, representing hope in the fight against the ongoing opioid crisis. Industry experts, stakeholders, and advocates look forward to exploring these advancements at the conference and beyond, reaffirming the importance of innovative solutions in public health.

For more information about CounterX Therapeutics, please contact Jacques Bouchy, Chief Business Officer, at 206-486-4755 or via email at [email protected].